The high-risk move one Australian company is hoping will pay off in the fight against COVID-19

the high risk move one australian company is hoping will pay off in the fight against covid 19

Sumary of The high-risk move one Australian company is hoping will pay off in the fight against COVID-19:

  • Coronavirus vaccines could be available by mid-next year, with an Australian company starting to make doses of one product before it has even been approved..
  • CSL is making about 30 million doses of the Oxford-AstraZeneca vaccine despite clinical trials continuing Results of the phase three clinical trials will not be known until the end of 2020 Early production of a yet to be approved vaccine is a high-risk strategy that could save thousands of lives The company, CSL, is making about 30 million doses of the Oxford-AstraZeneca vaccine despite it still going through phase-three clinical trials..
  • And if they’re positive, the vaccine will still need to get approval from the Therapeutic Goods Administration (TGA)..
  • “We’re making this ahead of time so should the clinical trial be positive with the outcome that we’re looking for … the vaccine will be available in the short term to distribute to the population,”.
  • Amanda Perobelli) “So it will deliver and manufacture the vaccine antigen to the person that’s been vaccinated, as distinct from some of the other vaccine technologies where we actually make the vaccine antigen known as the spike protein … outside the body, then we administer that to the recipient of the vaccine.”.
  • The gamble by the Federal Government and CSL means Australia has a chance to roll out the vaccine as soon as it becomes approved — assuming it gets past phase three trials and the TGA’s scrutiny..
  • “A vaccine would take at least six months to produce but by actually manufacturing and then stockpiling those vaccines now, we can get ahead,”.
  • “COVID-19 vaccines will be approved if they are 50 per cent effective at preventing the COVID-19 disease, not necessarily the infection,”.
  • The Federal Government has backed the University of Queensland’s protein-based vaccine as the home-grown trial of choice..
  • Lessons from the last big vaccine race Billions are being poured into the race to find a coronavirus vaccine, with the winner owning a powerful political tool..
  • Read more The Government has also secured 50 million potential vaccine doses through new agreements with companies Novavax and Pfizer/BioNTech, both of which are currently in stage three trials..
  • The Pfizer/BioNTech vaccine contains genetic material called mRNA — these vaccines effectively carry the molecular instructions to make the protein, so a person’s body can produce it, treat it as a foreign material and mount an immune response..
  • Australia has also handed over $123 million to join the global vaccines facility known as COVAX, a World Health Organization (WHO) initiative allowing all countries to share not only the costs of vaccine development, but also the benefits..
  • The money paid acts as a down payment, meaning if COVAX — which is working with CEPI, among others — develops a successful vaccine, Australia has a $123 million credit to spend on vaccine doses…

Want to know more click here go to health news source.

From -

Close

Languages